A clinical candidate must meet several criteria, such as dosing administration and frequency, in order to be selected as a lead candidate. It's critical to have a thorough understanding of the candidate's mechanism of action, assay results, and how it will fare in the market before deciding to proceed.
In this case study, we look at an example of targeting a membrane bound protein, which is often found to be involved in the pathogenesis of Immune thrombocytopenic purpura and Rheumatoid Arthritis, using a monoclonal antibody. Our customer’s candidate appears equipotent in a whole blood assay but significantly less potent than a competitor molecule in a target cell proliferation assay. The competitor molecule was 2 years ahead and a tighter binder. Our goal was to provide quantitative decision-making guidance using a systems pharmacology model to help the team answer questions such as if the project should be terminated, especially given the competitor's head start, or if a new lead generation campaign should be started to find a tighter binder.
- Our model analysis demonstrated that a weaker binder is a better molecule
- Customer molecule was not discarded, rather accelerated, and now positioned to be best-in-class